相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
Leo Timmers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
David P. Sonne et al.
REGULATORY PEPTIDES (2008)
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway
Amal K. Bose et al.
CARDIOVASCULAR DRUGS AND THERAPY (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
A phase of increased ST elevation during coronary occlusion following ischemic preconditioning
UM Mortensen et al.
BASIC RESEARCH IN CARDIOLOGY (2006)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model
AK Bose et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines
LA Nikolaidis et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Myocardial perfusion imaging with 99mTc sestamibi early after reperfusion reliably reflects infarct size reduction by ischaemic preconditioning in an experimental porcine model
J Kristensen et al.
NUCLEAR MEDICINE COMMUNICATIONS (2004)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Myocardial protection at a crossroads - The need for translation into clinical therapy
R Bolli et al.
CIRCULATION RESEARCH (2004)
Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
MA Nauck
HORMONE AND METABOLIC RESEARCH (2004)
GLP-1 and extra-islet effects
B Ahrén
HORMONE AND METABOLIC RESEARCH (2004)
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
M Kavianipour et al.
PEPTIDES (2003)
Role of β1- and β2-adrenoceptor subtypes in preconditioning against myocardial dysfunction after ischemia and reperfusion
C Frances et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2003)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects
B Elbrond et al.
DIABETES CARE (2002)
Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management
JA Beckman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Ischemic preconditioning: From adenosine receptor to K-ATP channel
MV Cohen et al.
ANNUAL REVIEW OF PHYSIOLOGY (2000)
分享论文
